Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 6 (1), 209-24

Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21 Century

Affiliations
Review

Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21 Century

Rafael Laniado-Laborín. Int J Environ Res Public Health.

Abstract

One hundred million deaths were caused by tobacco in the 20(th) century, and it is estimated that there will be up to one billion deaths attributed to tobacco use in the 21(st) century. Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis with smoking being recognized as its most important causative factor. The most effective available treatment for COPD is smoking cessation. There is mounting evidence that the rate of progression of COPD can be reduced when patients at risk of developing the disease stop smoking, while lifelong smokers have a 50% probability of developing COPD during their lifetime. More significantly, there is also evidence that the risk of developing COPD falls by about half with smoking cessation. Several pharmacological interventions now exist to aid smokers in cessation; these include nicotine replacement therapy, bupropion, and varenicline. All pharmacotherapies for smoking cessation are more efficacious than placebo, with odds ratios of about 2. Pharmacologic therapy should be combined with nonpharmacologic (behavioral) therapy. Unfortunately, despite the documented efficacy of these agents, the absolute number of patients who are abstinent from smoking at 12 months of follow-up is low.

Keywords: COPD; Tobacco; smoking; smoking cessation.

Figures

Figure 1
Figure 1
Global cigarette consumption. Increasing trend in the consumption of cigarettes (1880–2000)*. *Modified from Mackay, J.; Eriksen, M. The Tobacco Atlas © World Health Organization Publications.

Similar articles

See all similar articles

Cited by 42 PubMed Central articles

See all "Cited by" articles

References

    1. http://www.who.int/topics/tobacco/facts/en/index.htlm (accessed 28 November 2008).
    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–773. - PubMed
    1. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The Burden of Obstructive Lung Disease (BOLD) Initiative. Int. J. Tuberc. Lung Dis. 2008;12:703–708. - PubMed
    1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2008. - PubMed
    1. Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, López MV, Valvidia G, Montes de Oca M, Talamo C, Hallal PC, Victoria CG, PLATINO team Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875–1881. - PubMed

MeSH terms

Feedback